Kibow Therapeutics to Present Phase 2b Results for KT-301 in Stage 4 Chronic Kidney Disease at ASN Kidney Week 2026
Randomized, Double-Blind Phase 2b Data in 327 Patients, Plus New Mechanistic Research, to Be Presented October 23 in Denver EXTON, Pa., Oct. 21, 2026 /PRNewswire/ -- Kibow Therapeutics, a clinical-stage biotechnology company advancing microbiome-based therapies for chronic kidney disease...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.